# Arrowhead Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Arrowhead Pharmaceuticals, Inc). ## Overview Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes. Its pipeline spans 18 clinical-stage drug candidates across Phase 1 to Phase 3, supported by a broader discovery engine that is designed to generate new candidates each year. The company reached an important commercial milestone in 2025 with FDA approval of REDEMPLO (plozasiran) for familial chylomicronemia syndrome, marking its first marketed product. Alongside wholly owned programs, Arrowhead also monetizes its platform through collaboration and license agreements with large pharmaceutical partners such as Sarepta, Amgen, Takeda, GSK, and Novartis. ## Products & services • REDEMPLO (plozasiran) for familial chylomicronemia syndrome • RNAi drug discovery and preclinical candidate generation • Clinical-stage programs in rare and genetic diseases • Collaboration and license agreements with pharma partners • Commercialization and launch support for approved therapies - **Commercial product** (10%) — Approved RNAi therapy sold for familial chylomicronemia syndrome and supported by a newly built commercial organization. - **Collaborative licensing revenue** (75%) — Upfront, milestone, and other revenue from partnered programs with large pharmaceutical companies. - **Clinical-stage pipeline** (10%) — Wholly owned and partnered drug candidates in Phase 1 through Phase 3 development. - **Discovery platform** (5%) — Internal RNA chemistry and delivery platform used to generate new candidates for future development. - REDEMPLO (plozasiran) for familial chylomicronemia syndrome - RNAi drug discovery and preclinical candidate generation - Clinical-stage programs in rare and genetic diseases - Collaboration and license agreements with pharma partners - Commercialization and launch support for approved therapies ## Customers Arrowhead’s direct commercial customers are patients with rare lipid disorders, with REDEMPLO initially targeted at adults with familial chylomicronemia syndrome. In practice, the company’s commercial success also depends on physicians, specialty pharmacies, and third-party payers that influence prescribing, reimbursement, and distribution. A second major customer group is its pharmaceutical collaboration partners, which pay for access to Arrowhead’s RNAi platform and for development and commercialization rights to selected programs. These partners buy Arrowhead’s technology to accelerate their own pipelines in rare, genetic, and other high-value therapeutic areas while reducing the need to build comparable RNAi capabilities internally. - **Rare disease patients** (primary) — Patients with FCS and potentially sHTG who need triglyceride-lowering therapy and are the end users of REDEMPLO. - **Physicians and specialty prescribers** (primary) — Specialists who diagnose, prescribe, and monitor treatment in rare metabolic and genetic diseases. - **Specialty pharmacies and distributors** (primary) — Channel partners that dispense REDEMPLO and affect product availability, inventory, and sales timing. - **Third-party payers** (secondary) — Commercial and government payers that determine reimbursement access and patient affordability. - **Pharmaceutical collaboration partners** (primary) — Companies such as Sarepta, Novartis, GSK, Takeda, and Amgen that license Arrowhead programs and fund development. - Adults with familial chylomicronemia syndrome who may receive REDEMPLO - Patients with severe hypertriglyceridemia targeted for future expansion - Physicians and specialists who prescribe and manage rare disease therapy - Specialty pharmacies and distributors that handle product access and delivery - Pharmaceutical partners buying RNAi platform access and program rights - Payers that influence reimbursement and real-world uptake ## Geography Arrowhead is headquartered and primarily operates in the United States, where it maintains four facilities in California and Wisconsin. Its commercial launch of REDEMPLO is U.S.-focused, and its clinical, manufacturing, and corporate infrastructure is also concentrated domestically. The company’s collaboration partners are global pharmaceutical groups, so some program economics and regulatory activity extend beyond the U.S. even though the operating base is domestic. The concentration of facilities in the U.S. matters because manufacturing scale-up, clinical execution, and commercialization are all tied to a single-country operating footprint. - **United States** (100%) — Operations, facilities, and initial commercialization are centered in the U.S.; no country revenue split was disclosed. - Headquartered in the United States - Four U.S. facilities in Pasadena, San Diego, Madison, and Verona - Commercial launch of REDEMPLO is initially U.S.-based - Clinical development and manufacturing capacity are concentrated domestically - Global partners expand reach beyond the U.S. through collaborations ## Strategy Arrowhead’s strategy is to convert its RNAi platform into both proprietary medicines and partnered programs, using collaborations to fund development while retaining control of the most valuable assets. The first priority is to establish REDEMPLO as a commercial product in FCS and then expand into the larger sHTG market if Phase 3 and regulatory milestones are successful. A second priority is to deepen the pipeline by advancing multiple clinical candidates and continuing discovery work that can generate new programs each year. The company is also building manufacturing, sales, and customer support capabilities in-house while selectively outsourcing clinical trials and certain manufacturing activities to preserve flexibility and scale. - **Commercialize REDEMPLO in FCS** (short-term) — The company needs a successful first product launch to establish recurring product revenue and prove its commercial model. - **Expand into severe hypertriglyceridemia** (medium-term) — sHTG is a larger market than FCS and could materially broaden the commercial opportunity if Phase 3 and filing milestones are met. - **Monetize the RNAi platform through partnerships** (medium-term) — Collaborations provide non-dilutive capital and reduce the burden of funding every program internally. - **Scale manufacturing and operational infrastructure** (medium-term) — Commercial launch and late-stage development require more internal capacity, quality control, and supply reliability. - Build REDEMPLO into a durable commercial franchise in rare lipid disease - Expand from FCS into sHTG to address a larger patient population - Advance 18 clinical-stage candidates across multiple therapeutic areas - Use collaborations to monetize non-core programs and fund wholly owned assets - Increase in-house manufacturing capacity and commercialization readiness - Maintain a discovery engine that can generate new clinical candidates each year ## Risks Arrowhead remains highly dependent on successful clinical development, regulatory approvals, and commercial adoption of REDEMPLO and future products. Because the company is moving from a development-stage model into commercialization, execution risk is elevated in sales force build-out, payer access, specialty pharmacy distribution, and manufacturing reliability. It also relies heavily on third parties for clinical trials and certain manufacturing activities, so partner underperformance could delay programs or constrain supply. More broadly, biotechnology companies face binary trial outcomes, regulatory setbacks, pricing pressure, and reimbursement risk, while Arrowhead’s collaboration revenue can fluctuate materially based on the timing of milestone recognition and partner activity. - **Dependence on clinical-stage pipeline success** [high] — Most of the company’s value still depends on candidates that have not yet been approved or commercially proven. - **Commercial adoption risk for REDEMPLO** [high] — The company has limited prior commercialization experience and must build demand, reimbursement, and distribution from scratch. - **Third-party manufacturing and CRO dependence** [high] — Clinical supplies and some manufacturing are outsourced, so partner failures can delay development or constrain product availability. - **Specialty pharmacy and distributor concentration** [high] — The company expects to rely on Vanscoy Rare Pharmacy for a considerable portion of REDEMPLO sales, creating channel concentration risk. - **Regulatory and healthcare compliance** [medium] — Drug commercialization is subject to anti-kickback, fraud and abuse, and foreign corruption laws that can create liability and reputational damage. - Clinical trial failure or regulatory delay could stop or slow key programs - REDEMPLO adoption may be smaller than expected in a rare disease market - Commercial execution risk is high because the company is new to product launch - Third-party manufacturers and CROs could disrupt supply or trial timelines - Specialty pharmacy and payer behavior can create revenue volatility - Collaboration revenue can swing sharply with milestone timing and partner decisions ## Accounting Arrowhead’s reported results are highly sensitive to revenue recognition under collaboration and license agreements, because the company has only recently begun commercial sales and much of its revenue comes from partner contracts. The timing of upfront payments, milestones, and performance obligations can cause very large quarter-to-quarter swings, as seen in 2025 when revenue was driven primarily by Sarepta, Novartis, and GSK-related recognition. Investors should also watch the distinction between collaboration revenue and product revenue, since the mix affects margin quality and the sustainability of reported earnings. On the cost side, research and development spending, manufacturing build-out, and commercialization preparation create significant operating leverage, while lease accounting and capitalized facility investments affect the balance sheet and cash flow profile. - **Revenue recognition for collaboration agreements** — Major driver of reported revenue in 2025 - **Mix shift between collaboration revenue and product sales** — Affects revenue quality and gross margin trajectory - **R&D expense capitalization versus expensing** — Influences operating loss and cash burn - **Lease accounting and facility build-out** — Impacts balance sheet liabilities and future cash commitments - Collaboration and license revenue recognition can create large quarterly volatility - Upfront payments and milestones are recognized as performance obligations are satisfied - Product revenue from REDEMPLO is still early and may be lumpy due to launch dynamics - R&D expense remains the largest cost driver as programs move through trials - Manufacturing facility build-out and lease obligations affect cash needs and fixed-cost base - Commercial launch accounting may change as product sales become a larger share of revenue --- *Last updated: 2026-09-24T11:25:06.129767+00:00*